APA (7th ed.) Citation

Murakami, K., Sakurai, Y., Shiino, M., Funao, N., Nishimura, A., & Asaka, M. (2016). Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study. Gut, 65(9), 1439-1446. https://doi.org/10.1136/gutjnl-2015-311304

Chicago Style (17th ed.) Citation

Murakami, Kazunari, Yuuichi Sakurai, Madoka Shiino, Nobuo Funao, Akira Nishimura, and Masahiro Asaka. "Vonoprazan, a Novel Potassium-competitive Acid Blocker, as a Component of First-line and Second-line Triple Therapy for Helicobacter Pylori Eradication: A Phase III, Randomised, Double-blind Study." Gut 65, no. 9 (2016): 1439-1446. https://doi.org/10.1136/gutjnl-2015-311304.

MLA (9th ed.) Citation

Murakami, Kazunari, et al. "Vonoprazan, a Novel Potassium-competitive Acid Blocker, as a Component of First-line and Second-line Triple Therapy for Helicobacter Pylori Eradication: A Phase III, Randomised, Double-blind Study." Gut, vol. 65, no. 9, 2016, pp. 1439-1446, https://doi.org/10.1136/gutjnl-2015-311304.